Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14638243 | 0.75 | CYP4F2 (0.43) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 | |
| SCHEMBL27166892 | 0.73 | ALDH1A1 (0.31) | ALDH1A1LMNA | |
| SCHEMBL15603525 | 0.73 | CD274 (0.40) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 | |
| SCHEMBL20389670 | 0.73 | ALDH1A1 (0.38) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 | |
| SCHEMBL12497507 | 0.72 | CYP4F2 (0.45) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 | |
| SCHEMBL25196116 | 0.72 | ALDH1A1 (0.38) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 | |
| SCHEMBL1144773 | 0.70 | LMNA (0.41) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 | |
| SCHEMBL19253462 | 0.69 | CYP4F2 (0.38) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 | |
| SCHEMBL8002700 | 0.68 | CYP4F2 (0.50) | CYP4F2CYP4A11ATR | |
| SCHEMBL19253411 | 0.68 | CYP4F2 (0.33) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| CN-118574809-A | 4-Phenyl-2- (1H-1, 2, 3-triazol-4-yl) piperidin-4-ol derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
| WO-2023102022-A1 | 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102022-A1 | 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, RNASE1 | ALDH1A1 4089/4885LMNA 2182/4885POLB 2958/4885 |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | APOL1, RNASE1, LOXL1 | ALDH1A1 3134/4885LMNA 1246/4885POLB 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.